证券代码：833266 证券简称：生物谷 公告编号：2025-018 云南生物谷药业股份有限公司 关于拟向兴业银行申请授信额度的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、向兴业银行申请授信的基本情况 为满足公司生产经营及业务发展需要，公司 2025 年拟向兴业银 行申请融资额度不超过人民币 3000 万元的综合授信额度（包括新增 及原授信到期后的展期），授信种类包括流动贷款、票据池服务等。 具体融资额度将视公司的实际经营需求及兴业银行实际审批的授信 额度为准，该额度在授信期限内可循环使用（即有效期内任何时点融 资额度不超过人民币 3000 万元）。授权有效期为自公司第五届董事会 第四次会议审议通过之日起一年内有效，董事会授权公司董事长会同 经营层在授权范围内审批相关流程，并签署有关合同及文件。 二、审议情况和表决情况 1、公司于 2025 年 4 月 24 日召开第五届董事会审计委员会第四 次会议，审议通过《关于 2025 年度拟向兴业银行申请授信额度的议 案》，表决结果为：同意 3 票 ...

云南生物谷药业股份有限公司 2024年度 财务报表出具非标审计报告的 专项说明 索引 页码 专项说明 1-3 关于云南生物谷药业股份有限公司 XYZH/2025SZAA8B0211 云南生物谷药业股份有限公司 2024 年度财务报表出具非标审计报告的专项说明 云南生物谷药业股份有限公司全体股东： 我们接受委托审计了云南生物谷药业股份有限公司（以下简称"生物谷公司"或"公 司"）财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度的合并 及母公司利润表、合并及母公司现金流量表、合并及母公司股东权益变动表，以及相关财 务报表附注，并于 2025 年 4 月 25 日出具了 XYZH/2025SZAA8B0216 号保留意见的审计报告。 根据中国证券监督委员会《公开发行证券的公司信息披露编报规则第 14 号-非标准审 计意见及其涉及事项的处理》（2020 年修订）、《监管规则适用指引—审计类第 1 号》及《北 京证券交易所股票上市规则（试行）》的相关要求，就相关事项说明如下： 一、 审计报告中保留意见的内容 如审计报告中"形成保留意见的基础"部分所述，公司原控股股东深圳市金沙江投 ...

一、本次股票解除限售数量总额为 864,984 股，占公司总股本 0.698%， 可交易时间为 2025 年 4 月 9 日。 二、本次股票解除限售的明细情况及原因 单位：股 | | | 是否为控 | | | | 本次解 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 股东姓名 | 股股东、 | 董事、监 事、高级 | 本次解限 | 本次解除 | 除限售 股数占 | 尚未解除 | | 序号 | | 实际控制 | | | 限售登记 | | 限售的股 | | | 或名称 | 人或其一 | 管理人员 | 售原因 | 股票数量 | 公司总 | 票数量 | | | | 致行动人 | 任职情况 | | | 股本比 | | | | | | | | | 例 | | | | | | 原董事、 | | | | | | 1 | 杨智玲 | 否 | 原高级管 | B | 107,150 | 0.086% | 321,450 | | | | | 理人员 | | | | | | | | | 原董事、 | | | | | | 2 | 邓慧明 | 否 | 原高级管 | B ...

关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 云南生物谷药业股份有限公司（以下简称"公司"）于2025年4 月1日收到保荐机构国新证券股份有限公司（以下简称"国新证券"） 出具的《关于云南生物谷药业股份有限公司持续督导保荐代表人变 更的函》。国新证券担任公司于2020年7月向不特定合格投资者公开 发行股票并在精选层挂牌的持续督导机构，曾指定梁立群女士、张 见先生作为该次精选层挂牌的保荐代表人具体开展持续督导工作。 现张见先生因退休，不再担任公司持续督导的保荐代表人。为保证 持续督导工作有序进行，国新证券委派付玉龙先生为公司持续督导 的保荐代表人，继续履行持续督导义务。 本次变更后，公司的持续督导保荐代表人为梁立群女士和付玉 龙先生。本次变更不影响国新证券对公司的持续督导工作，公司董 事会对张见先生在担任公司保荐代表人期间所做的工作表示衷心的 感谢！ 证券代码：833266 证券简称：生物谷 公告编号：2025-005 云南生物谷药业股份有限公司 云南生物谷药业股份有限 ...

Financial Performance - The total revenue for the reporting period was CNY 516,232,107.07, a decrease of 17.05% compared to the previous year[4] - The net profit attributable to shareholders was CNY -68,883,069.87, representing a decline of 464.60% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -75,357,038.91, down 228.80% from the previous year[4] - The basic earnings per share were CNY -0.56, a decrease of 460.00% compared to the same period last year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 1,149,313,345.38, a decline of 6.99% year-on-year[6] - The equity attributable to shareholders was CNY 930,595,180.34, down 6.89% compared to the beginning of the period[6] Bad Debt Provision - The company recorded a bad debt provision of CNY 66.82 million during the reporting period, compared to CNY 43.69 million in the previous period[7] Revenue Decline Factors - The decline in revenue was primarily due to price reductions for core products, including the "Dengzhanbai Capsule" and "Dengzhanxixin Injection" due to intensified competition in the healthcare environment[7] Corporate Governance - The company plans to continue monitoring and addressing the fund occupation issues with its former controlling shareholder, Shenzhen Jinsijiang Investment Co., Ltd.[8] Investment Caution - The financial data presented is preliminary and has not been audited, and investors are advised to be cautious regarding investment risks[9]

证券代码：833266 证券简称：生物谷 公告编号：2025-002 云南生物谷药业股份有限公司 股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、本次股票解除限售数量总额为 55,162 股，占公司总股本 0.04%， 可交易时间为 2025 年 2 月 25 日。 二、本次股票解除限售的明细情况及原因 注：解除限售原因： A 董事、监事、高级管理人员每年解除限售 B 离职董事、监事、高级管理人员解除限售 C 自愿限售解除限售 D 限制性股票解除限售 E 公开发行前特定主体股票解除限售上市 F 参与战略配售取得股票解除限售上市 G 其他（说明具体原因） | 无限售条件的股份 | 76,990,252 | 62.09% | | --- | --- | --- | | 1、高管股份 有限售条件的 | 14,158,536 | 11.42% | | 2、个人或基金 | 0 | 0% | | 3、其他法人 | 32,851,219 | 26.49% | | 股份 4、限制性股票 | 0 | ...

Financial Performance - The company's net profit attributable to shareholders is expected to be between -75.28 million and -61.60 million CNY, compared to -12.20 million CNY in the same period last year, representing a change of -517.06% to -404.87%[5] - The decline in revenue is primarily due to the dual impact of industry and centralized procurement policies, leading to price reductions for core products such as Lingzhan Shenmai Capsules and Lingzhan Xixin Injection[6] - The company has recognized a bad debt provision of 66.82 million CNY during the reporting period, compared to 43.69 million CNY in the previous period, with a cumulative bad debt provision of 200.46 million CNY[6] Audit and Reporting - The financial data presented is preliminary and has not been audited by an accounting firm, and the final figures will be disclosed in the company's 2024 annual report[7] Corporate Governance - The company is actively pursuing the resolution of fund occupation issues with its former controlling shareholder, Shenzhen Jinsanjiang Investment Co., Ltd., and its actual controller, Lin Yanhe[6]

证券代码：833266 证券简称：生物谷 公告编号：2024-089 云南生物谷药业股份有限公司 第五届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 2.议案表决结果：同意 3 票；反对 0 票；弃权 0 票。 会议应出席监事 3 人，出席和授权出席监事 3 人。 全体监事均以通讯方式参与表决。 1.会议召开时间：2024 年 10 月 25 日 2.会议召开地点：网络 3.会议召开方式：通讯方式 4.发出监事会会议通知的时间和方式：2024 年 10 月 15 日 以通讯方 式发出 5.会议主持人：监事会主席许晓森先生 6.召开情况合法、合规、合章程性说明： 二、议案审议情况 （一）审议通过《关于 2024 年第三季度报告》议案 1.议案内容： 根据《北京证券交易所股票上市规则（试行）》《北京证券交易所 上市公司持续监管指引第 2 号——季度报告》等相关规定及要求，公 司 2024 年第三季度报告已编制完毕。 具体内容详见于公司 ...

证券代码：833266 证券简称：生物谷 公告编号：2024-088 云南生物谷药业股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 10 月 25 日 2.会议召开地点：网络 3.会议召开方式：通讯方式 会议应出席董事 9 人，出席和授权出席董事 9 人。 全体董事均以通讯方式参与表决。 二、议案审议情况 （一）审议通过《关于 2024 年第三季度报告的议案》 4.发出董事会会议通知的时间和方式：2024 年 10 月 15 日以通 讯方式发出 5.会议主持人：董事长林弘威先生 6.会议列席人员：公司监事及高级管理人员 7.召开情况合法、合规、合章程性说明： 本次会议的召集、召开及议案审议程序符合《公司法》及《公司 章程》的相关规定，会议的召集、召开及表决合法有效。 （二）会议出席情况 三、备查文件目录 1、《云南生物谷药业股份有限公司第五届董事会第三次会议决议》； 2、《云南生物谷 ...

Financial Performance - Operating revenue for the first nine months of 2024 was CNY 420,136,311.75, down 10.46% from CNY 469,237,445.29 in the same period of 2023[4] - Net profit attributable to shareholders for the first nine months of 2024 was CNY 1,790,516.28, a decline of 70.38% compared to CNY 6,044,110.41 in 2023[4] - Basic earnings per share for the third quarter of 2024 was CNY 0.01, down 80.00% from CNY 0.05 in the same period of 2023[4] - The company reported a net loss attributable to shareholders of CNY 3,011,174.86 for the third quarter of 2024, a decrease of 130.02% compared to a profit of CNY 10,031,027.91 in the same period of 2023[4] - Total operating revenue for the first nine months of 2024 was CNY 420.14 million, a decrease of 10.5% compared to CNY 469.24 million in the same period of 2023[26] - Net profit for the first nine months of 2024 was CNY 1.79 million, a decline of 70.4% compared to CNY 6.04 million in the same period of 2023[27] - The company’s total profit for the first nine months of 2024 was CNY 2.75 million, down 68.4% from CNY 8.70 million in the same period of 2023[27] Cash Flow - Cash flow from operating activities for the first nine months of 2024 was CNY 100,844,264.39, a decrease of 11.44% compared to the previous year[4] - Cash inflow from operating activities totaled 509,116,550.03, down from 599,808,337.30 in the same period last year, representing a decrease of approximately 15%[31] - Cash outflow from operating activities was 408,272,285.64, compared to 485,934,433.34 in the previous period, indicating a reduction of about 16%[33] - Net cash flow from operating activities was 100,844,264.39, down from 113,873,903.96, reflecting a decline of around 11%[33] - Cash inflow from investment activities was 51,516,457.44, an increase from 32,157,106.06, marking a growth of approximately 60%[33] - Net cash flow from investment activities was -11,200,822.82, improving from -72,098,317.71 in the previous period[33] - Cash inflow from financing activities was 6,267,394.50, compared to 58,300.00 in the previous period, showing a significant increase[33] Assets and Liabilities - Total assets as of September 30, 2024, amounted to CNY 1,214,099,292.79, a decrease of 1.75% compared to CNY 1,235,702,221.84 at the end of 2023[4] - The company's total liabilities to total assets ratio (consolidated) was 17.53% as of September 30, 2024, down from 19.12% at the end of 2023[4] - Current liabilities decreased from 99,104,080.81 to 95,532,408.80, a reduction of about 5.1%[21] - Non-current liabilities decreased from 137,119,890.82 to 117,298,117.50, a decrease of approximately 14.4%[21] - The company’s total liabilities decreased from 236,223,971.63 to 212,830,526.30, a reduction of about 9.9%[22] Shareholder Information - The total number of unrestricted shares decreased from 77,640,137 to 76,935,090, a change of -0.91%[11] - The total share capital remained unchanged at 124,000,007 shares[11] - Major shareholders include Shanghai Xinhong Pharmaceutical Co., Ltd. with 26.49% ownership and Li Zhensheng with 8.15% ownership[12] Related Party Transactions and Legal Matters - The company has engaged in related party transactions, which were disclosed and executed in a timely manner[16] - The company has fulfilled its commitments as disclosed in previous announcements, including those from 2015 and 2020[16] - There were no significant litigation or arbitration matters reported during the period[16] Research and Development - Research and development expenses decreased by 37.23% to CNY 9,208,001.89, primarily due to amortization based on contract and project progress[7] - Research and development expenses for the first nine months of 2024 were CNY 9.21 million, a decrease of 37.5% compared to CNY 14.67 million in the same period of 2023[26] Financial Obligations and Guarantees - The company provided a guarantee for a project loan of up to 120 million CNY for the "Yunnan Biological Valley Health Industry Park Project," with an actual guarantee amount of 90 million CNY as of the reporting period[17] - In 2021, the original controlling shareholder, Jinsha River, occupied funds amounting to 67,115,237.50 CNY, with repayments of 39,061,315.34 CNY, and in January 2022, occupied funds of 11,649,139.54 CNY with repayments of 39,703,061.70 CNY[17] - As of the reporting date, Jinsha River had not repaid a total of 257 million CNY of occupied funds and corresponding financial returns[17] - The company has made provisions for bad debts totaling 143.92 million CNY due to the large amount of funds occupied by Jinsha River[18] - The company has taken legal action against Jinsha River and related parties to recover the occupied funds, with the Shenzhen Intermediate People's Court accepting the case in August 2022[18] - The company has pledged assets held by Jinsha River to secure the repayment of occupied funds, including 99% equity in two companies and receivables totaling 29.19 million CNY[18] - The company has maintained communication with Jinsha River and Mr. Lin Yanhe to resolve the fund occupation issue[18] - The company has not experienced significant operational disruptions due to the fund occupation, and the financial impact has been managed[18] - The company continues to monitor the progress of related criminal cases concerning fund occupation to facilitate recovery efforts[18]